Grufity logoGrufity logo

PSNL

2.51USD+0.18(+7.73%)Market Closed

Personalis Inc

Market Summary

USD2.51+0.18Market Closed
7.73%

PSNL Stock Price

RSI Chart

Valuation

Market Cap

122.6M

Price/Earnings

-1.31

Price/Sales

1.6

Price/Cashflow

-1.71

MarketCap/EBT

-1.31

Price/Sales

Profitability

Operating Margin

32.22%

EBT Margin

-122.49%

Return on Equity

-35.38%

Return on Assets

-26.15%

Fundamentals

Revenue

Revenue (TTM)

69.0M

Revenue Y/Y

-33.26%

Revenue Q/Q

-18.54%

Earnings

Earnings (TTM)

-102.4M

Earnings Y/Y

-49.93%

Earnings Q/Q

3.83%

Price Action

52 Week Range

2.1815.28
(Low)(High)

Last 7 days

-10.7%

Last 30 days

5.9%

Last 90 days

-33.4%

Trailing 12 Months

-82.0%

Financial Health

Current Ratio

6.27

Investor Care

Shares Dilution (1Y)

2.65%

Diluted EPS (TTM)

-2.27

Peers (Alternatives to Personalis)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
41.1B
6.7B
17.42% 0.84%
30.93
6.17
8.42% 34.14%
38.7B
14.3B
21.25% -17.93%
32.72
2.7
5.70% 54.11%
36.7B
4.7B
0.68% -39.28%
-1.9K
7.81
9.79% -558.28%
10.9B
3.8B
20.03% -34.84%
24.61
2.96
10.37% 10.04%
MID-CAP
6.9B
1.4B
37.93% 2.91%
30.49
5.03
25.69% 24.11%
5.2B
5.4B
-27.37% -66.03%
18.72
0.96
8.57% 14.42%
SMALL-CAP
2.0B
137.0M
37.63% -54.74%
-9.53
14.05
12.61% -709.53%
1.1B
159.7M
25.76% -69.37%
-4.68
6.81
19.67% -35.56%
616.1M
123.7M
3.59% -52.65%
-13.85
5.59
43.31% -77.98%
555.2M
520.0M
36.23% -84.01%
-0.18
1.11
19.60% -686.73%
372.0M
132.7M
2.06% -85.10%
-19.64
2.76
31.03% -107.73%
122.6M
69.0M
5.91% -82.01%
-1.31
1.6
-18.80% -75.52%

Financials for Personalis

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue-9.7%6976808585
  S&GA Expenses4.6%6057534845
  R&D Expenses2.2%6362574943
Earnings Before Taxes-9.4%-102.42-93.59-81.01-65.21-58.33
Net Income-9.4%-102.45-93.62-81.03-65.23-58.37
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-11.2%318358381397407
  Current Assets-14.7%222260294318329
    Cash Equivalents-3.7%84879210680
  Net PPE28.7%6148312018
Liabilities-19.2%7593948681
  Current Liabilities-18.7%3442403127
Shareholder's Equity-8.4%242265287310325
  Retained Earnings-8.7%-329.34-302.85-275.30-247.09-226.90
  Additional Paid-In Capital0.8%573569563558552
Accumulated Depreciation7.5%2423211917
Shares Outstanding0.1%4646454545
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations4.3%-68.74-71.86-70.44-70.83-58.09
  Share Based Compensation4.3%1817161414
Cashflow From Investing-21.1%718919-60.07-163.12
Cashflow From Financing135.3%217170169

Risks

What is the probability of a big loss on PSNL?

98.9%


Probability that Personalis stock will be more than 20% underwater in next one year

97.2%


Probability that Personalis stock will be more than 30% underwater in next one year.

95.6%


Probability that Personalis stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does PSNL drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Personalis was unfortunately bought at previous high price.

Returns

Cumulative Returns on PSNL

-34.1%


3-Year Cumulative Returns

Which funds bought or sold PSNL recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-15
FRED ALGER MANAGEMENT, LLC
ADDED
-
-100,000
621,000
-%
2022-11-15
STATE STREET CORP
REDUCED
-2.08
-65,000
351,000
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%
2022-11-15
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO
REDUCED
-46.99
-90,000
76,000
-%
2022-11-15
ALGERT GLOBAL LLC
ADDED
172.07
97,000
169,000
0.01%
2022-11-15
JACOBS LEVY EQUITY MANAGEMENT, INC
REDUCED
-65.69
-1,956,000
820,000
0.01%
2022-11-15
JANE STREET GROUP, LLC
REDUCED
-53.9
-142,000
93,000
-%
2022-11-15
BNP PARIBAS ARBITRAGE, SNC
REDUCED
-96.43
-34,376
1,090
-%
2022-11-14
MORGAN STANLEY
REDUCED
-35.95
-481,000
595,000
-%
2022-11-14
GABELLI FUNDS LLC
REDUCED
-20.72
-100,000
214,000
-%

1–10 of 47

Latest Funds Activity

Are funds buying PSNL calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own PSNL

Personalis News

The News Heater

Personalis Inc. (PSNL): Skating on Thin Ice? We Know the Answer.100 minutes ago

PSNL Fair Value

Recent SEC filings of Personalis

View All Filings
Date Filed Form Type Document
Nov 18, 2022
4
Insider Trading
Nov 18, 2022
4
Insider Trading
Nov 18, 2022
4
Insider Trading
Nov 16, 2022
8-K
Current Report
Nov 02, 2022
10-Q
Quarterly Report
Nov 02, 2022
8-K
Current Report
Oct 31, 2022
8-K
Current Report
Oct 03, 2022
8-K
Current Report
Sep 22, 2022
4
Insider Trading
Sep 22, 2022
4
Insider Trading

Latest Insider Trading transactions for PSNL

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-16
Chen Richard
SOLD
-3,509.45
2.71
-1,295
Chief Medical Officer
2022-11-16
Moore Stephen Michael
SOLD
-5,541.95
2.71
-2,045
General Counsel
2022-11-16
Tachibana Aaron
SOLD
-3,506.74
2.71
-1,294
Chief Financial Officer
2022-09-20
Tachibana Aaron
SOLD
-12,089.5
3.48
-3,474
Chief Financial Officer
2022-09-20
Chen Richard
SOLD
-5,501.88
3.48
-1,581
Chief Medical Officer
2022-09-02
Tachibana Aaron
SOLD
-13,879.4
3.33
-4,168
Chief Financial Officer
2022-09-02
Chen Richard
SOLD
-1,398.6
3.33
-420
Chief Medical Officer
2022-08-15
Moore Stephen Michael
ACQUIRED
-
-
18,600
General Counsel
2022-08-15
West John Stephen
ACQUIRED
-
-
230,000
President and CEO

1–10 of 50

John S. West
330
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.

PSNL Income Statement

2022-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]    
Revenue$ 14,858$ 22,261$ 48,325$ 64,812
Costs and expenses    
Cost of revenue12,37914,19537,28741,151
Research and development14,95713,61748,34334,800
Selling, general and administrative14,78112,14046,14133,989
Total costs and expenses42,11739,952131,771109,940
Loss from operations(27,259)(17,691)(83,446)(45,128)
Interest income743881,236286
Interest expense(45)(60)(154)(125)
Other income (expense), net805149(43)
Loss before income taxes(26,481)(17,658)(82,215)(45,010)
Provision for income taxes11123217
Net loss$ (26,492)$ (17,670)$ (82,247)$ (45,027)
Net loss per share, basic$ (0.58)$ (0.40)$ (1.81)$ (1.03)
Net loss per share, diluted$ (0.58)$ (0.40)$ (1.81)$ (1.03)
Weighted-average shares outstanding, basic45,921,41144,511,53445,518,33443,579,308
Weighted-average shares outstanding, diluted45,921,41144,511,53445,518,33443,579,308

PSNL Balance Sheet

2022-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets  
Cash and cash equivalents$ 83,522$ 105,585
Short-term investments109,234181,479
Accounts receivable, net13,59218,468
Inventory and other deferred costs7,5435,610
Prepaid expenses and other current assets8,0177,089
Total current assets221,908318,231
Property and equipment, net61,21919,650
Operating lease right-of-use assets30,04553,822
Other long-term assets4,6894,825
Total assets317,861396,528
Current liabilities  
Accounts payable10,7849,221
Accrued and other current liabilities22,65818,110
Contract liabilities2973,982
Total current liabilities33,73931,313
Long-term operating lease liabilities41,34952,797
Other long-term liabilities3742,117
Total liabilities75,46286,227
Commitments and Contingencies (Note 9)
Stockholders’ equity  
Common stock, $0.0001 par value - 200,000,000 shares authorized; 45,955,866 and 44,904,512 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively54
Additional paid-in capital573,158557,558
Accumulated other comprehensive loss(1,422)(166)
Accumulated deficit(329,342)(247,095)
Total stockholders’ equity242,399310,301
Total liabilities and stockholders’ equity$ 317,861$ 396,528